Sukumar Nagendran, Director at Taysha Gene Therapies, Inc. (TSHA), bought 10,000 shares at $8.01 ($80K) on 2022-02-02, disclosed to the SEC on 2022-02-03.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| TSHA | SELL | 2026-01-27 | $547K | — | Filing → |
| TSHA | SELL | 2026-01-14 | $942K | — | Filing → |
| TSHA | SELL | 2025-12-01 | $3.4M | — | Filing → |